• Publications
  • Influence
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conductedExpand
  • 802
  • 50
  • PDF
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor prognosis. The chimericExpand
  • 354
  • 32
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Accurate identification of patients likely to achieve long-progression-free survival (PFS) after chemoimmunotherapy is essential given the availability of less toxic alternatives, such as ibrutinib.Expand
  • 307
  • 17
  • PDF
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
In this study, we analyzed the long-term outcome of a risk-adapted transplantation strategy for mantle cell lymphoma in 121 patients enrolled in sequential transplantation protocols. NotableExpand
  • 180
  • 14
  • PDF
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Early results of the fludarabine, cyclophosphamide, and rituximab (FCR) regimen in 224 patients showed that it was highly active as initial therapy of chronic lymphocytic leukemia. In this report, weExpand
  • 658
  • 13
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
BACKGROUND Selective BCL2 inhibition with venetoclax has substantial activity in patients with relapsed or refractory chronic lymphocytic leukaemia. Combination therapy with rituximab enhancedExpand
  • 192
  • 12
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ and γ (PI3K-δ,γ) being developed for treatment of hematologic malignancies. PI3K-δ,γ signaling canExpand
  • 96
  • 7
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
To the editor: The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib sets a new standard of care for the treatment of patients with relapsed or refractory chronic lymphocytic leukemiaExpand
  • 187
  • 7
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma
The combination of fludarabine, cyclophosphamide, and rituximab (FC‐R) shows significant in vitro synergism and may improve patient outcome with little overlapping toxicity.
  • 96
  • 7